Hypothalamic Inhibition Of Acetyl-coa Carboxylase Stimulates Hepatic Counter-regulatory Response Independent Of Ampk Activation In Rats. by Santos, Gustavo A et al.
Hypothalamic Inhibition of Acetyl-CoA Carboxylase
Stimulates Hepatic Counter-Regulatory Response
Independent of AMPK Activation in Rats
Gustavo A. Santos1., Vinı´cius D. Pereira1., Erika A. F. R. Roman1, Leticia Ignacio-Souza1,
Daniele C. Vitorino , Rodrigo Ferreira de Moura , Daniela S. Razolli , Adriana S. Torsoni  ,2 1 1 3
3*
1 Faculdade de Cieˆncias Me´dicas, Universidade Estadual de Campinas, Campinas, Sa˜o Paulo, Brazil, 2 Instituto de Biologia, Universidade Estadual de Campinas, Campinas,
Sa˜o Paulo, Brazil, 3 Faculdade de Cieˆncias Aplicadas, Universidade Estadual de Campinas, Limeira, Sa˜o Paulo, Brazil
Abstract
Background: Hypothalamic AMPK acts as a cell energy sensor and can modulate food intake, glucose homeostasis, and
fatty acid biosynthesis. Intrahypothalamic fatty acid injection is known to suppress liver glucose production, mainly by
activation of hypothalamic ATP-sensitive potassium (K(ATP)) channels. Since all models employed seem to involve malonyl-
CoA biosynthesis, we hypothesized that acetyl-CoA carboxylase can modulate the counter-regulatory response
independent of nutrient availability.
Methodology/Principal Findings: In this study employing immunoblot, real-time PCR, ELISA, and biochemical
measurements, we showed that reduction of the hypothalamic expression of acetyl-CoA carboxylase by antisense
oligonucleotide after intraventricular injection increased food intake and NPY mRNA, and diminished the expression of
CART, CRH, and TRH mRNA. Additionally, as in fasted rats, in antisense oligonucleotide-treated rats, serum glucagon and
ketone bodies increased, while the levels of serum insulin and hepatic glycogen diminished. The reduction of hypothalamic
acetyl-CoA carboxylase also increased PEPCK expression, AMPK phosphorylation, and glucose production in the liver.
Interestingly, these effects were observed without modification of hypothalamic AMPK phosphorylation.
Conclusion/Significance: Hypothalamic ACC inhibition can activate hepatic counter-regulatory response independent of
hypothalamic AMPK activation.
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Introduction
The hypothalamus actively participates in energy expenditure,
satiety signals and counter-regulatory response [1–3]. Neuropep-
tides such as NPY, AGRP, POMC and CART are known to be
expressed in the hypothalamic nucleus, to participate in the
regulatory mechanism of energy expenditure, satiety signals and
counter-regulatory response, and be modulated by hormones and
nutrients.
AMP-activated protein kinase (AMPK) can integrate signaling
circuits between peripheral tissues and the hypothalamus to
regulate food intake and whole-body energy expenditure [3,4].
This important cell energy sensor can activate the catabolic
pathways that produce ATP when energy availability is low. On
the other hand, when energy is sufficient for cellular activity, it
shuts down pathways that produce energy [5]. Additionally,
hypothalamic AMPK has an important role in the expression of
hypothalamic neuropeptides [6–8] and counter-regulatory re-
sponse [2], modulating energy expenditure and plasma concen-
trations of corticosterone, glucagon, and catecholamines.
Acetyl-CoA carboxylase (ACC) is responsible for catalyzing the
reaction that produces malonyl-CoA, an intermediate in the
biosynthesis of fatty acids. ACC is an AMPK target, which
phosphorylates on Ser72 and thereby inactivates ACC under
conditions of energy surplus [9]. Several studies have shown that
pharmacological activation of AMPK, which promotes the
inhibition of ACC and a decrease in hypothalamic levels of
malonyl-CoA, leads to an increase in food intake [10,11].
Furthermore, recently Kinote and colleagues showed that fructose
activates hypothalamic AMPK and stimulates hepatic PEPCK
and gluconeogenesis [12]. On the other hand, refeeding and fatty
acid synthase inhibitor increase the hypothalamic availability of
malonyl-CoA and decrease food intake [13–16]. The hypotha-
lamic level of malonyl-CoA increases (4.0-fold) in response to
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transition from fasted to fed state. In fasted rats, the reduction of
hypothalamic level of malonyl-CoA occurs even in the presence of
acetyl-CoA [17].
Hypothalamic lipid metabolism is important for the control of
energy metabolism [18–20]. Obici and colleagues demonstrated
that oleic acid [21] and inhibition of carnitine palmitoyltransfer-
ase-1 [22] decrease food intake and liver glucose production. More
recently, Ross and collaborators demonstrated differential effects
of hypothalamic long-chain fatty acid infusion on the glucose
production [23]. In this study, they showed that a low dose of oleic
acid administered to the medium basal hypothalamus is sufficient
to markedly reduce liver glucose production, whereas a poly-
unsaturated fatty acid (linoleic acid) and a saturated fatty acid
(palmitic acid) did not show any effect or only in high dose,
respectively. Mammalian cells are not capable of producing
polyunsaturated fatty acids, but the biosynthesis of saturated and
monounsaturated fatty acids that occurs in the cytoplasm is very
important for this pathway.
We hypothesized that inhibition of ACC independent of
nutritional status and AMPK activation has an important role in
the positive modulation of hepatic counter-regulatory response. To
test this hypothesis, intracerebroventricular injection of antisense
oligonucleotide (ASO) to acetyl-CoA carboxylase (ACC) was
performed in rats with free access to food; the analyses were
performed at noon because it is a time when the animal has no
counter-regulatory stimulus resulting from long fasting.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations of the COBEA (Brazilian College of Animal
Experimentation) guidelines, which was approved by the Ethical
Committee for Animal Use (ECAU) (ID protocol: 1970–1) of the
Universidade Estadual de Campinas (UNICAMP), Campinas, Sa˜o
Paulo, Brazil.
Animals and Surgical Procedures
Male Wistar rats (12 wk old, 250–280 g) were taken from the
University’s central breeding colony and maintained in poly-
propylene cages in a room at 2461uC with lights on from 6:00 to
18:00 h and fed diets and water ad libitum. The rats were
chronically instrumented with an ICV cannula and kept under
controlled temperature and light-dark conditions in individual
metabolic cages. Surgery was performed under anesthesia, and all
efforts were made to minimize animal suffering. Briefly, the
animals were anesthetized with 50 mg/kg ketamine and 5 mg/kg
diazepam (ip) and positioned onto a Stoelting stereotaxic
apparatus after the loss of cornea and foot reflexes. A stainless
steel 23 gauge guide cannula with an indwelling 30 gauge
obturator was stereotaxically implanted into the lateral cerebral
ventricle at pre-established coordinates, anteroposterior, 0.2 mM
from bregma, lateral, 1.5 mM; and vertical, 4.2 mM, according to
a previously reported technique [24]. The cannulas were
considered patent and correctly positioned by dipsogenic response
elicited after injection of angiotensin II (2 mL of solution 1026 M)
[25]. After test for cannula function and position, rats were
randomly assigned to one of the experimental groups.
Food intake and Body Weight Measures
Body weight was evaluated from the first to the fourth days of
treatment with ASO. Food intake was evaluated on the third day
after the ACC-ASO administration was started. Pre-weighed food
was provided in individual cages 10 min before the start dark
period. Cumulative food intake was measured after 12 h by
weighing the residual food in the cages. The amounts of food left
over on the bottom of the cages were recorded. Intake was
calculated as the weight (g) of food provided less that recovered.
AICAR Injection
The fed rats received 3 mL of bolus injection of 2 mmol/L 5-
amino-1-b-D-ribofuranosyl-imidazole-4-carboxamide (AICAR)
into the lateral ventricle.
Sense (SO) and Antisense Oligonucleotide (ASO)
Injection
Phosphorothioate-modified sense and antisense oligonucleo-
tides (produced by IDT, Munich, Germany) were diluted to
a final concentration of 1 nmol/mL in dilution buffer containing
10 mmol/L Tris–HCl and 1.0 mmol/L EDTA. The oligonu-
cleotides sequences consisted of 59-GCC AGT CAG TAA GAG
CAG-39 (sense) and 59-TGA GAT CTG CAA TGC A-39
(antisense). Wistar rats were injected into the lateral ventricle
with two daily doses of 4 nmoles oligonucleotides in dilution
buffer containing either sense (ACC-SO) or antisense oligonu-
cleotides (ACC-ASO) for three days. Fragments of liver and
hypothalamus were obtained at about 12:00 h on the fourth day
of treatment with oligonucleotide. The animals were provided
free access to water and rat chow. Control animals received
saline solution.
Pyruvate Challenge
Rats with free access to food were injected intraperitoneally
with sodium pyruvate (0.5 g/kg). Blood samples were collected
from the tail vein immediately before and at various time points
(0–120 min) after the pyruvate load to measure blood glucose.
Tissue Extraction and Immunoblotting
The rats were anesthetized after specific treatments and tissue
samples were obtained and homogenized in freshly prepared ice
cold buffer (1% Triton X 100, 100 mM TRIS, pH 7.4,
100 mM sodium pyrophosphate, 100 mM sodium fluoride,
10 mM EDTA, 10 mM sodium vanadate, 2 mM PMSF, and
0.01 mg aprotinin.mL21). The insoluble material was removed
by centrifugation (10,000 g) for 25 min at 4uC. The protein
concentration in the supernatant was determined by the
Bradford dye-binding method. The supernatant was resus-
pended in Laemmli sample buffer and boiled for 5 min before
separation in SDS PAGE using a miniature slab gel apparatus
(Bio Rad, Richmond, CA). Electrotransfer of proteins from the
gel to nitrocellulose was performed for 90 min at 120 V
(constant). The nitrocellulose transfers were probed with specific
antibodies. The phophoenolpyruvate carboxykinase (PEPCK)
and glyceraldeyde-3-phosphate dehydrogenase (GAPDH) anti-
bodies were obtained from Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA. The total AMP activated protein (AMPK),
phospho-AMPK (p-AMPK), total ACC (ACC) and phospho-
ACC antibodies were obtained from Cell Signaling Technology,
Inc., Danvers, MA. Subsequently, the blots were incubated with
HRP-conjugate antibodies (KPL, Gaithersburg, MD- USA). The
results were visualized by autoradiography with preflashed
Kodak XAR film. Band intensities were quantified by optical
densitometry of developed autoradiographs (Scion Image
software, ScionCorp) and the intensities of the bands were
normalized to those of either total protein or GAPDH to
correct for protein loading in the case of cellular lysate extracts.
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Immunofluorescence Staining
For histological evaluation, hypothalamic tissue samples were
fixed in 4% formaldehyde and processed routinely for embedding
in paraffin block. The samples were dehydrated (alcohol at 70, 80,
90, 95%, and absolute), diaphanized by immersion in xylol, and
embedded in paraffin. Hydrated (alcohol at absolute, 95, 90, 80,
and 70%) 5.0-mm paraffin sections were processed for immuno-
fluorescence staining. The expression of ACC (Cell Signaling
Technology, Inc., Danvers, MA) was analyzed employing goat
anti-rabbit-FITC was used as secondary. The images were
obtained using a Leica FW 4500 B microscope, software LAS
V3.8.
Real Time PCR Analysis
Hypothalamic total RNA was extracted using Trizol reagent
(Life Technologies, Gaithersburg, MD, USA) according to the
manufacturer’s recommendations. Total RNA was rendered
genomic DNA-free by digestion with Rnase-free Dnase (RQ1,
Promega, Madison, WI, USA). Reverse-transcription was per-
formed using total RNA from hypothalamic samples. Intron-
skipping primers for NPY, POMC, CART, TRH, and CRH
mRNAs were obtained from Applied Biosystems. Real-time PCR
analysis of gene expression was performed in an ABI Prism 7700
sequence detection system (Applied Biosystems, California). The
optimal cDNA and primer concentrations, as well as the
maximum efficiency of amplification, were obtained through
five-point, two-fold dilution curve analysis for each gene. Each
PCR contained 20 ng of reverse-transcribed RNA and was run
according to the manufacturer’s recommendation using the
TaqMan PCR Master Mix (Applied Biosystems, California).
Target mRNA expression was normalized to GAPDH expression
and expressed as a relative value using the comparative threshold
cycle (Ct) method (22DDCt) according to the manufacturer’s
instructions.
Biochemical and Hormonal Measurements
Blood glucose was determined using a glucometer. Serum
insulin, glucagon, and corticosterone were analyzed simultaneous-
ly and measured in duplicate at all time points using a commer-
cially available rat endocrine Linco-plex kit (Rendo-85 K, Linco
Research, St Charles, MO, USA). All blood samples were
collected from the tail vein.
For the determination of the level of hepatic glycogen, a tissue
fragment was evaluated as described by Burant and colleagues
[26].
Data Presentation and Statistical Analysis
All numerical results are expressed as means 6 SE of the
indicated number of experiments. Blot results are presented as
direct band comparisons in autoradiographs and quantified by
densitometry using the Scion Image software (ScionCorp).
Student’s t-tests of unpaired samples and variance analyses
(ANOVA) for multiple comparisons were used as appropriate.
Post hoc test (Tukey) was employed when required at significance
level of p,0.05.
Results
AMPK Phosphorylation and ACC Expression
Initially, we evaluated the levels of hypothalamic phosphoryla-
tion of AMPK and the expression of ACC. As expected, fasted rats
showed higher AMPK phosphorylation than fed rats. The ICV
treatment of fed rats with either antisense or sense oligonucleotide
(ASO and SO, respectively) to ACC proteins did not affect the
hypothalamic phosphorylation of AMPK (Fig. 1A). In addition, we
evaluated the effect of intracerebroventricular (ICV) injection of
ACC-ASO (antisense oligonucleotide) on the hypothalamic,
hippocampal and brainstem expression of ACC. For this purpose,
rats were treated with either antisense or sense oligonucleotide
(4 nmol/animal) twice a day for three days. As shown in Fig. 1B,
the ACC-ASO treatment reduced ACC expression in the
hypothalamus by 50%, when compared to both the control group
(treated with saline) and the ACC-SO group (sense nucleotide). As
expected, the treatment with ACC-SO did not affect the
expression of ACC. ACC expression was also evaluated in the
brainstem and hippocampus of control and ACC-ASO rats. As
shown in Fig. 1C, ACC-ASO rats presented reduced ACC
expression when compared to control rats in both investigated
areas. Furthermore, to evaluate whether the ACC-ASO treatment
affected the neuronal populations in the arcuate nucleus (ARC),
paraventricular nucleus (PVH) and lateral hypothalamus (LH)
differently, we performed immunoflorescence staining of hypo-
thalamus samples from control and ACC-ASO rats. ACC
expression was detected in all studied nuclei. However, as
expected, it decreased in the ARC, PVH and LH after
administration of ACC-ASO (Fig. 1D).
Food intake, Body Weight and Epididymal Fat Mass
Food intake was measured on the third night after the treatment
with ACC-ASO had been started. As can be observed in Fig. 2A,
rats treated with ACC-ASO presented higher food intake
(20.060.7 g/12 h) than control (saline) and ACC-SO
(15.961.3 g/12 h and 16.061.0 g/12 h, respectively). At the
end of the experimental period, the epididymal fat mass and body
weight gain were measured. Figure 2B shows that the treatment
with ACC-ASO diminished epididymal fat mass (1.560.4 g),
when compared to control (5.060.8 g) and ACC-SO animals
(4.560.7 g). Furthermore, we evaluated body weight gain.
Although, body weight gain was lower in ACC-ASO than in
control and ACC-SO rats, the difference was not significant
(Fig. 2C).
Real Time Analysis of Gene Expression
CART, TRH, and CRH mRNA were measured in the
hypothalamus by real time PCR. As shown in Figure 3, the
treatment with ACC-ASO significantly decreased gene expression
of neuropeptides CART (50%), TRH (70%), and CRH (40%)
(Figs. 3A, B, and C, respectively). On the other hand, NPY
expression increased (2.7-fold) in ACC-ASO rats when compared
to control rats. POMC mRNA was not different among the
evaluated groups. Interestingly, the analysis of gene expression in
fasted rats revealed a behavior similar to that of rats treated with
ACC-ASO. ACC-SO treatment did not alter the expression of any
of the hypothalamic neuropeptides evaluated.
Serum Hormone Level
Serum glucagon, insulin, and corticosterone levels were
quantified on the fourth day. The animals had previous free
access to chow and blood samples were collected at 12:00 h.
The serum corticosterone level was not affected by the
treatments with ACC-ASO, ACC-SO, or saline ICV (data not
shown). However, the serum level of glucagon in the ACC-ASO
group (14.962.7) was higher than in the control and ACC-SO
groups (6.261.5 and 4.062.3 pmol.L21, respectively), but it was
similar in the fasted group (11.864.0 pmol.L21) (Fig. 4A). On
the other hand, the serum level of insulin for ACC-ASO was
similar to that of fasted animals (204638 and
1946102 pmol.L21, respectively), but smaller than the control
Hypothalamic ACC Modulates Glucose Production
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and ACC-SO treatment values (4596215 and
6486114 pmol.L21, respectively) (Fig. 4B). Interestingly, the
blood level of ketone bodies increased in the ACC-ASO group
relative to the control and ACC-SO groups (0.4760.11,
0.2960.07 and 0.3260.09 mmol.L21, respectively) (Fig. 4C).
The hepatic glycogen store was reduced in ACC-ASO
(20.165.0 mg.g21 of tissue) when compared to control and
ACC-SO rats (3567 and 3463 mg.g21 of tissue, respectively)
(Fig. 4D).
Hepatic Gluconeogenic Profile
To assess whether the liver presented counter-regulatory
activity, we evaluated the expression of PEPCK and the capacity
of the liver to produce glucose after administration of pyruvate,
a gluconeogenic substrate. As can be observed in Figure 5A, the
expression of hepatic PEPCK increased significantly (by seven-
fold) after treatment with ACC-ASO when compared to control
animals, and so did the phosphorylation of AMPK and ACC
(Fig. 5B). The treatment with ACC-SO, as expected, did not exert
any effect on PEPCK expression and AMPK and ACC
phosphorylation relative to control and ACC-SO.
To evaluate liver glucose production, rats received intraperito-
neal injection of sodium pyruvate and blood glucose was measured
(Fig. 6A and B). As can be observed in Figures 6A and 6B, the
glycemic curve and the area under the curve (AUC) were greater
in the group treated with ACC-ASO than with ACC-SO and
control (39606700, 28006400, 23406450, respectively). Addi-
tionally, we evaluated the glycemic curve and AUC in rats
previously ICV treated with AICAR, a pharmacological activator
of AMPK. As expected, the increase in blood glucose was higher if
compared to ACC-SO and control rats.
Discussion
The results presented in this study demonstrate the role of
hypothalamic acetyl-CoA carboxylase (ACC) in the control of
hepatic glucose production. The studies performed so far have
demonstrated the participation of AMPK in the modulation of
food intake and glucose homeostasis by different mechanisms in
the hypothalamus [1–3,16,18,21–23,27]. A common feature to
Figure 1. Modulation of AMPK/ACC pathway in central nervous system of ACC-ASO and ACC-SO mice. Representative western blot of
hypothalamic p-AMPK (A) and ACC (B) in fasted and fed rats, ACC-ASO (ASO) and ACC-SO (SO). Representative western blot of hippocampus and
brainstem area of ACC (C). Representative ACC immunoflorescence staining (green) of samples from hypothalamus (ARC, LH and PVH) of Wistar rats.
Cell nuclei were counterstained with DAPI (blue) (D). Bars show quantification of total p-AMPK and ACC proteins normalized by either total GAPDH or
AMPK. Data are means 6 SEM of five rats. (A)*p#0.05 vs. control fed, ASO and SO. (B)*p#0.05 vs. control and SO.
doi:10.1371/journal.pone.0062669.g001
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mechanisms proposed is the modulation of the hypothalamic level
of malonyl-CoA. The biosynthesis of malonyl-CoA is controlled by
ACC, a key enzyme in the control of biosynthesis of fatty acid and
widely expressed in different tissues. Activated AMPK phosphor-
ylates (at ser79) and inhibits ACC, leading to a reduction in the
level of malonyl-CoA. The hypothalamic activity of AMPK
increases during fasting and decreases during refeeding [4]. To
investigate the hypothesis that the hypothalamic level of malonyl-
CoA can modulate liver glucose production, we initially evaluated
the hypothalamic phosphorylation of AMPK in fasted and freely
fed rats (light cycle). As expected, fasted rats showed greater
AMPK phosphorylation than fed rats. Reduced AMPK phos-
phorylation is linked to an increase in ACC activity and
biosynthesis of malonyl-CoA. Tokutake and colleagues showed
that the hypothalamic level of malonyl-CoA is modulated by the
fasting/feeding transition in rats [17]. Interestingly, although the
Figure 2. Anthropometric evaluation and feeding behavior in ASO-ACC and ACC-SO mice. Food intake (A), epididymal fat mass (B) and
body weight (C) in control, ACC-ASO (ASO) and ACC-SO (SO) rats. Data are means 6 SEM of 8–10 rats. (A)*p#0.05 vs. control and SO rats.
doi:10.1371/journal.pone.0062669.g002
Figure 3. mRNA level of neuropeptides in hypothalamus from ASO-ACC and ACC-SO mice. Analyses of CART, TRH, CRH and NPY mRNA
expression in the hypothalamus of control, ACC-ASO (ASO) and ACC-SO (SO) rats by RT-PCR. Data are means 6 SEM of 8–10 rats. #p#0.05 and
*p#0.01.
doi:10.1371/journal.pone.0062669.g003
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hypothalamic level of malonyl-CoA was modified by the fasting/
feeding state, the acetyl-CoA level was not altered. To test the
hypothesis that the reduction of hypothalamic ACC activity in fed
rats would be enough to activate a counter-regulatory response, we
injected ICV ACC-ASO in the light cycle in freely fed rats.
Although, ACC-ASO injection did reduce hypothalamic ACC
protein, it did not affect the hypothalamic phosphorylation of
AMPK (Figs. 1A and B). Interestingly, the level of phospho-ACC
(inactive form) was not different between groups (data not shown).
This result reinforces the idea that treatment with ACC-ASO
diminished the availability of active ACC and, consequently, of
malonyl-CoA to the cells.
In an elegant study in Kahn’s Lab, Minokoshi and colleagues
demonstrated that constitutively active-AMPK mice ate more and
had increased expression of NPY and AGRP mRNA in ARC [4].
The increase in the AMPK activity was linked to diminished ACC
activity, mimicking a fasting condition. In our study, ACC-ASO
rats also presented reduced hypothalamic ACC expression (green),
if compared to control rats (free access to food) and ACC-SO
(Fig. 1B and 1D) in all nuclei studied (ARC, PVH and LH).
Furthermore, ACC-ASO also decreased ACC expression in the
brainstem and hippocampus (Fig. 1C). Interestingly, lower
hypothalamic CART, CRH, and TRH mRNA levels and
increased NPY mRNA, an orexigenic neuropeptide, accompanied
this effect. CART, CRH, and TRH mRNA present reduced
hypothalamic expression in response to fasting and leptin [28,29].
Furthermore, it is important to point out that the analyses were
performed in the light cycle, a period of reduced food intake [30].
Figure 4. Biochemical parameters in ASO-ACC and ACC-SO mice. Serum glucagon (A) and insulin level (B), blood ketone bodies (C), and
hepatic glycogen (D) in control (fed), ACC-ASO (ASO), ACC-SO (SO) and fasted rats. Data are means6 SEM of 8–10 rats. (A) *p#0.01 to ASO and fasted
vs. control and SO. (B) *p#0.05 vs. ASO and fasted. (C and D) *p#0.05 vs. control and SO.
doi:10.1371/journal.pone.0062669.g004
Figure 5. Liver PEPCK expression and AMPK/ACC phosphorylation in ASO-ACC and ACC-SO mice. Representative western blot of PEPCK
(A). Bars show quantification of total PEPCK protein normalized by total GAPDH. Representative western blot of p-AMPK and p-ACC protein
normalized by total GAPDH (B). Data are means 6 SEM of 4–6 rats. *p#0.05 vs. control and ACC-SO rats.
doi:10.1371/journal.pone.0062669.g005
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Although ACC-ASO-treated rats had free access to food, they
presented gene expression similar to those of fasted rats (higher
NPY level). Additionally, they did not show difference in body
weight (Fig. 2C) but epididymal fat mass was reduced (Fig. 2B),
due to reduced expression of CART, TRH, and CRH, three
neuropeptides linked to pro-thermogenic metabolism and anorex-
igenic behavior [31,32]. Therefore, these results reinforce the role
of malonyl-CoA as a hypothalamic indicator of energy homeosta-
sis. Although, reduced epididymal fat mass seems to be contra-
dictory, since ACC-ASO rats presented higher food intake than
control rats (Fig. 2A), the increased lipolysis observed, as indicated
by reduced epididymal fat pad, may be due to increased serum
levels of glucagon observed in ACC-ASO rats. Furthermore,
although the body weight gain was similar, we believe that three
days were insufficient to affect body weight gain.
In fasting state, the hepatic metabolism shifts toward fat
oxidation and synthesis of glucose as part of a counter-regulatory
hormonal response. This shift in metabolism is important for the
energy homeostasis, in which the hypothalamus has a fundamental
role. Han and colleagues showed that pharmacological inhibition
of hypothalamic AMPK or ARC/VMH DN-AMPK overexpres-
sion attenuated hypoglycemia-induced increases in plasma con-
centrations of corticosterone, glucagon, and catecholamine [2].
They concluded that systemic hypoglycemia causes hypothalamic
activation of AMPK, which is important for counter-regulatory
hormonal responses. In addition, recently, Kawashima and
colleagues showed that hypothalamic AMPK activation by
glucopenia occurs via a CaMKK-independent pathway [33] and
that another AMPK upstream kinase might be involved in 2DG
activation of AMPK, such as LKB1 [34]. Considering that ACC-
ASO-treated rats mimic fasting condition, we compared their
hormonal profile to that of fasted rats. ACC-ASO-treated rats
presented reduced serum insulin and hepatic glycogen accompa-
nied by increased serum glucagon, ketone bodies, and AUC in the
pyruvate test (Figs. 4 and 6), typical hormonal and biochemical
responses to fasting condition. Therefore, these results suggest that
modulation of the hypothalamic activity of ACC may be able to
trigger a counter-regulatory response, independent of the avail-
ability of nutrients, and hypothalamic phosphorylation of AMPK.
In recent years, many studies have shown that the hypothal-
amus participates in the modulation of hepatic glucose production
by activation of hypothalamic ATP-sensitive potassium (K(ATP))
channels and parasympathetic signals delivered by the vagus nerve
[35–38], which is associated with reduced hepatic expression of
gluconeogenic genes, glucose-6-phosphatase (G6Pase), and phos-
phoenolpyruvate carboxykinase (PEPCK). The liver is known to
play an important role in glucose homeostasis through gluconeo-
genesis [39]. In ACC-ASO-treated rats, liver expression of
PEPCK increased (Fig. 5A) corroborating the results of pyruvate
tolerance test. These effects were accompanied by increase in liver
AMPK and ACC phosphorylation in ACC-ASO-treated rat
(Fig. 5B). Liver activation of AMPK is linked to diminished
expression of gluconeogenic enzymes [40] and phosphorylation of
glycogen synthase 1 [41], which reduces the glucose output from
the liver. Furthermore, the increase in the blood level of ketone
bodies (Fig. 4C), as well as ACC inactivation in the liver (Fig. 5B),
suggests that fatty acid oxidation is increased under ACC-ASO,
when compared to control and ACC-SO groups.
Thus, we believe that the hypothalamic levels of ACC protein
and malonyl-CoA are important signals to control liver glucose
production by an AMPK-independent mechanism. Although
AMPK surely is an important nutrient and energy sensor that
maintains energy homeostasis, many proteins can be modulated
by kinase activity of AMPK. Thus, in the cell, it can modulate the
pathway related to protein synthesis, mitochondrial biogenesis,
fatty acid and glucose metabolism, and autophagia [42].
Therefore, ACC may be a better target to control the hepatic
metabolism than AMPK.
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